Market revenue in 2023 | USD 140.0 million |
Market revenue in 2030 | USD 215.5 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.71% in 2023. Horizon Databook has segmented the Argentina rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
Understanding the trends in the rheumatoid arthritis therapeutics market in Argentina requires a nuanced approach. While specific data for Argentina may be limited, insights can be gleaned from broader pharmaceutical trends and regional developments. In recent years, the adoption of biosimilar drugs has been gaining traction globally, offering more affordable alternatives to branded biologics.
This trend could potentially impact the RA therapeutics market in Argentina as biosimilars become more widely available and accepted. Additionally, the Argentine healthcare system has been undergoing reforms aimed at improving access to essential medicines, which could positively influence the availability and affordability of RA treatments.
Collaborations between pharmaceutical companies and healthcare providers may also play a crucial role in raising awareness and promoting the use of effective therapies for RA in Argentina. However, regulatory hurdles and economic fluctuations may pose barriers to market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Argentina rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account